Tag Archive for: Novartis

LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease

/in

Financing led by leading life sciences venture capital firm Forbion, with participation from existing investors SV Health Investors’ Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF) Lead programme targeting MutSβ set to enter the clinic in 2026, offering a potentially disease-modifying therapy for Huntington’s disease Forbion General Partner Rogier Rooswinkel joins Board of Directors […]

Read more

Radio what’s new? Tuning in to turning cancer cells off

/in

Tuning in to the field of targeted cancer medicine through molecular radiotherapy or targeted radionuclides.

Read more

Applications for BaseLaunch Phase II accelerator program to close on 22nd June

/in

This is a fantastic initiative that helps young businesses by providing the support they need to succeed. This includes up to USD 500,000 in fundraising, introduction to a dynamic network and access to free lab space.

Read more